Key Clinical Message:
Managing adult-onset Still’s disease (AOSD) complicated by severe hepatitis requires vigilant monitoring and adaptable therapeutic strategies. Standard treatments like Tocilizumab and Rituximab can cause adverse reactions or lose efficacy. The interplay of systemic inflammation and liver involvement highlights the need for ongoing research to find effective, safe treatment alternatives.